Skip to NavigationSkip to content

NICE greenlights Consilient Health's Elmiron for bladder pain syndrome

Published on 14/11/19 at 12:09pm

NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it has emerged, for patients whose condition has not responded to oral treatments and are not offered the drug in combination with bladder instillations.

The decision was reached as the two parties agreed to a patient access scheme to make the drug available to NHS patients.

In regards to the decision, BPS is defined as chronic pain, discomfort or pressure in the pelvic region combined with at least one other urinary symptom.

“This is a condition with a significant unmet clinical need and the company is delighted that Elmiron has been recommended for the treatment of IC/BPS,” commented Amanda Paxon, Country Manager, Pharmaceuticals at Consilient Health UK.

Susannah Fraser, Communication and Media Manager at Bladder Health UK, also remarked on the news: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals to be able to access Elmiron on the NHS is really good news.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches